

## The mouse homolog of FRG1, a candidate gene for FSHD, maps proximal to the myodystrophy mutation on Chromosome 8

Prabhjit K. Grewal,<sup>1</sup> Judith C.T. van Deutekom,<sup>2</sup> Kate A. Mills,<sup>3</sup> Richard J.L.F. Lemmers,<sup>2</sup> Kathy D. Mathews,<sup>3</sup> Rune R. Frants,<sup>2</sup> Jane E. Hewitt<sup>1</sup>

<sup>1</sup>School of Biological Sciences, The University of Manchester, 3.239 Stopford Building, Oxford Road, Manchester, M13 9PT, UK

<sup>2</sup>MGC-Department of Human Genetics, Sylvius Laboratory, Leiden University Leiden, The Netherlands

<sup>3</sup>Department of Pediatrics, University of Iowa, Iowa City, Iowa USA

Received: 24 September 1996 / Accepted: 7 February 1997

**Abstract.** The human autosomal dominant neuromuscular disorder facioscapulohumeral muscular dystrophy (FSHD) is associated with deletions within a complex tandem DNA repeat (D4Z4) on Chromosome (Chr) 4q35. The molecular mechanism underlying this association of FSHD with DNA rearrangements is unknown, and, thus far, no gene has been identified within the repeat. We isolated a gene mapping 100 kb proximal to D4Z4 (FSHD Region Gene 1:FRG1), but were unable to detect any alterations in total or allele-specific mRNA levels of FRG1 in FSHD patients. Human Chr 4q35 exhibits synteny homology with the region of mouse Chr 8 containing the gene for the myodystrophy mutation (*myd*), a possible mouse homolog of FSHD. We report the cloning of the mouse gene (*Frg1*) and show that it maps to mouse Chr 8. Using a cross segregating the *myd* mutation and the European Collaborative Interspecific Backcross, we showed that *Frg1* maps proximal to the *myd* locus and to the *Clc3* and *Ant1* genes.

### Introduction

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder characterized by progressive weakness and atrophy of the face, shoulder girdle, and upper arm muscles (Lunt and Harper 1991). The locus for FSHD has been mapped to human Chr 4q35 and is associated with deletions within a 3.3-kb tandem repeat, D4Z4 (van Deutekom et al. 1993). Despite extensive analysis of this D4Z4 locus, no gene has been found to reside there (Hewitt et al. 1994; Altherr et al. 1995; Lyle et al. 1995). However, considering the association of sequences related to D4Z4 with heterochromatic regions of the genome, a position effect variegation model has been proposed as the underlying genetic mechanism for FSHD (Hewitt et al. 1994; Winokur et al. 1994; Lyle et al. 1995).

The search for genes in the FSHD candidate region has been hindered by the presence of high and low copy number repeats (Altherr et al. 1995; van Deutekom et al. 1995). Despite this, we recently reported the isolation and characterization of the first FSHD candidate gene (FRG1;FSHD Region Gene 1) located approximately 100 kb centromeric of the repeat units (van Deutekom et al. 1996). Although allele-specific RT-PCR experiments suggested that transcript levels of FRG1 were not affected by FSHD-associated deletions, we could not exclude the possibility of a subtle change in transcription levels (van Deutekom et al. 1996).

The spontaneously arising mouse mutation, myodystrophy (*myd*), maps to mouse Chr 8 (Lane et al. 1976; Mathews et al. 1995b), which shows homology of synteny with distal human Chr 4q. *myd* is flanked distally by mitochondrial uncoupling protein

(*Ucp*) with a homolog on human 4q31 and proximally by chloride channel 3 (*Clc3*) and coagulation factor XI (*Cf11*), genes with homologs on human 4q32 and 4q35 respectively (Mathews et al. 1995b; Mills et al. 1995, 1996b). The *myd* mutation may be homologous to FSHD. The isolation of FRG1 thus provided a promising candidate gene for involvement in *myd*. The aim of this study was to isolate the mouse homolog of FRG1 and map its position relative to the *myd* locus.

### Materials and methods

**PCR analysis of somatic cell hybrid panel.** The CV panel of mouse × Chinese hamster somatic cell hybrids (Williamson et al. 1995) was used for chromosomal assignment of mouse *Frg1*. DNA from this panel was obtained from the MRC HGMP Resource Center. PCR primers used: GEGF: 5' AGAAATCTTAAAAAGGCTCGG 3'; GEG2R: 5' AAGCTACACAAAATGTCCACG 3'. These primers amplified a 1500-bp product in mouse CBA/H DNA; no product was amplified in hamster V79 TOR DNA. Fifty nanogram of template DNA was used in a final reaction volume of 25 µl containing 10 mM Tris-HCl pH 8, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 150 ng of each primer, and 0.5 U Taq polymerase (Bioline, London). The PCR was carried out in a Hybaid Omnigene Thermocycler for 30 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s extension at 72°C for 30 s.

**Screening cDNA libraries.** The 1.5-kb GEG2 PCR product, precompeted with mouse Cot1 DNA (Gibco BRL, Paisley) for 1.5 h at 65°C, was used as a probe to screen a 10-dpc mouse embryo cDNA library cloned into λSH/lox vector (Novagen). Final washes were performed at 65°C in 0.5–1 × SSC, 0.1% SDS for 30 min. Four positive plaques were picked and suspended in SM buffer 100 mM NaCl, 10 mM MgSO<sub>4</sub>, 35 mM Tris[pH 7.5] and rescreened twice before further analysis.

**Genetic mapping of *Frg1*.** DNA samples, prepared by the European Collaborative Interspecific Backcross (EUCIB) between laboratory strain C57BL/6 and *Mus spretus* (Breen et al. 1994), were obtained from the MRC HGMP Resource Centre. Using the PCR conditions described for the STS GEG2, a product was amplified from the parental strains. Although the two species did give slightly different-sized products, the difference between the two strains was too small to resolve accurately on agarose gels; therefore, an *Hae*III polymorphism was used. PCR product was digested with 1U of the restriction enzyme *Hae*III in a total volume of 30 µl for at least 1 h to identify the polymorphism. Several constant bands were produced, with strain-specific fragments of 750 bp and 1 kb in C57BL/6 and *M. spretus* respectively. Both fragments could be clearly identified in heterozygotes. Samples were scored on 3% NuSieve (Flowgen) gel stained with ethidium bromide. A polymorphism was produced for *Ant1* based on the genomic structure of the human ANTI gene (Li et al. 1989) and the mouse mRNA sequence deposited in GenBank (Accession no. U27315). Mouse-specific PCR primers (*AntF*: 5' GCTGCCAGACCCCAAGAATG 3'; *AntR*: 5'GTCCCCGTGTACATAATATC 3') amplify a product of approximately 1 kb from mouse genomic DNA with PCR conditions as



**Table 1.** PCR analysis of *Frg1* with a mouse/hamster somatic cell hybrid panel. The table shows the mouse chromosome content of each hybrid cell line. '+' and '-' indicate presence or absence of the chromosome, respectively. (+) indicates that the chromosome is thought to be present in only a portion of the cells. (±) indicates that inconsistent results have been reported in previous PCR experiments. Cell lines are indicated as to whether they were positive or negative for the GEG2 PCR product. Discordance for each chromosome is given underneath.

Hybrid name	Mouse chromosome																			GEG2		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		X	Y
MH1	+	-	-	-	-	-	-	(+)	-	-	-	-	-	+	-	+	-	+	-	+	+	-
MH2	-	-	-	-	-	+	+	-	-	-	-	-	+	+	-	+	+	-	-	+	-	-
MH3	-	-	-	-	-	+	+	-	-	-	-	-	+	+	-	+	-	-	-	+	-	-
MH4	-	-	+	-	-	+	-	-	-	-	-	-	+	+	-	+	+	-	+	+	+	-
MH6	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	+	-	-	-	+	+	-
MH7	-	-	+	-	-	+	-	-	-	-	-	-	+	+	-	+	+	-	+	+	+	-
MH8	+	+	-	+	-	+	-	-	-	-	-	-	+	+	+	-	+	-	-	+	+	-
MH9	+	+	-	+	-	+	-	-	-	-	-	-	+	+	+	-	+	-	-	+	+	-
MH12	-	+	-	+	-	+	-	-	-	-	-	-	+	+	-	+	+	-	-	+	+	-
MH13	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	+	-	-	-	+	+	-
MH14	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+	+	-
MH15	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	+	+	-
MH18	+	+	-	+	-	+	+	+	-	+	-	+	+	+	+	-	-	-	+	+	+	+
MH19	+	+	-	+	-	+	+	+	-	+	-	+	+	+	+	-	+	-	+	+	+	+
MH20	-	+	-	+	-	+	+	+	-	+	-	+	+	+	+	-	-	-	-	+	+	+
MH21	-	-	+	-	-	+	+	+	-	-	-	-	-	+	-	±	-	+	-	+	+	+
MH22	-	-	-	-	-	+	+	+	-	-	-	-	+	+	-	+	+	+	-	+	+	+
MH23	-	-	+	-	-	+	+	-	-	-	-	-	+	+	-	+	+	+	-	+	+	-
MH24	-	-	-	-	-	+	+	-	-	-	-	-	+	+	-	+	+	+	-	+	+	-
MH25	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	+	+	+	-	+	+	-
MH26	±	-	+	+	+	+	+	-	+	-	+	+	-	-	+	-	-	+	+	+	-	-
MH27	+	(+)	+	+	+	+	+	-	+	-	-	+	+	-	+	-	+	+	+	+	-	-
Discordance	11/22	6/22	9/22	7/22	7/22	11/22	6/22	1/22	6/22	3/22	5/22	4/22	13/22	14/22	6/22	15/22	12/22	9/22	7/22	16/22	14/22	

MC10 is the mouse homolog of FRG1, and we have designated this gene *Frg1*. Within the coding region, the human and mouse cDNAs have 90% nucleotide identity, but there is no significant homology in either the 5' or 3' untranslated regions. The *Frg1* protein contains a high percentage of charged amino acids (38%). Searching of protein databases revealed no significant homology to any known proteins or protein domains.

**Mapping of *Frg1* to mouse Chr 8.** To determine the chromosomal location of *Frg1*, we analyzed the mouse-hamster somatic cell hybrid panel of Williamson and associates (1995) using the GEG2 PCR. The data are consistent with *Frg1* mapping to Chr 8 (Table 1). Importantly, this result showed this STS to be locus specific; co-amplification of closely related loci on other chromosomes had complicated analysis of the human gene (van Deutekom et al. 1996).

**Fine genetic mapping.** The *Frg1* polymorphism was used to type 68 random backcross progeny from the European Collaborative Interspecific Backcross (EUCIB) (Breen et al. 1994). Linkage was found between *Frg1* and mouse Chr 8 markers, confirming the somatic cell hybrid panel localization. To refine the location of *Frg1* and to determine its relationship to *myd*, we then also typed these mice using D8Mit markers known to be closely linked to *myd* (Mills et al. 1995). In addition, the location of *Frg1* was determined with respect to *Clc3* and *Ant1*, mouse genes with human homologs on 4q32 and 4q35 respectively (Mills et al. 1996a, 1996b).

Figure 2A shows a genetic map of the region of mouse Chr 8 containing *Frg1* determined in the EUCIB. Haplotype data are shown in Fig. 2B. This map places *Frg1* outside the *myd* critical region as it is proximal to *D8Mit9*, which is completely linked to *myd* (Mathews et al. 1995a). Furthermore, both *Ant1* and *Clc3* map between *Frg1* and *D8Mit9*. The order of markers is in agreement with the MIT map (Dietrich et al. 1996) and previously published maps of this region (Mathews et al. 1995a; Mills et al. 1995, 1996a, 1996b); the only major difference being that in the EUCIB cross three recombination events were identified placing *D8Mit261* proximal to *D8Mit9*, while these markers are unordered in the MIT map.


**Mapping of *Frg1* in a cross segregating the *myd* mutation.** To confirm that the *Frg1* gene maps outside the region containing the *myd* locus, we then used the B6C3-CAST cross described in Materials and methods. Figure 2C shows the localization of *Frg1* by haplotype analysis in a subset of animals from this cross that are recombinant in the interval of interest. None of the genotyping of the 100 other chromosomes contradicted the location of *Frg1* based on the recombinants. Additional animals have been typed to confirm marker order (data not shown). The major difference between the two maps is that *D8Mit224* is proximal to *Frg1* in the B6C3-CAST cross, whereas no recombinants between these markers were identified in our study. The location of *Frg1* relative to *D8Mit192* and *D8Mit9* in both maps is in agreement. Four affected animals which showed recombination events proximal to the mutation and distal to *Frg1* were identified.

**Northern blot analysis.** Although the genetic mapping has placed the *Frg1* gene proximal to the *myd* mutation, we were aware that a possible disease mechanism for FSHD is a long-range position effect. As a similar mechanism could also be occurring in the mouse, we investigated the expression of the *Frg1* gene in normal and *myd* mice by Northern blot analysis (Fig. 3). A single transcript of approximately 1.2 kb was detected in all tissues analyzed, with highest levels of expression in testis. No significant differences in *Frg1* mRNA levels were seen in homozygous *myd* mice compared with controls.

## Discussion


On the basis of the high level of sequence conservation and mapping of the mouse gene to the region with homology of synteny on Chr 8, we have isolated a cDNA for the mouse homolog of the human FRG1 gene. FRG1 is highly conserved between human and mouse with only eight amino acid differences, the majority of which are conservative substitutions.

The Northern blots showed no evidence of alternative splicing of *Frg1*, which differs from the findings of López-Alanón and del Mazo (1995), who used EST X71639 as a probe and identified



**Fig. 2.** Genetic mapping of *Frg1*. (A) Partial Chr 8 linkage map (95% confidence limits) based on typing 68 random mice from the EUCIB. Genetic distances (in centimorgans) and standard errors are listed to the left. (B) Haplotype of animals in EUCIB. Black and white squares represent loci typed as homozygous or heterozygous, respectively. Hatched boxes indicate unknown genotype. The number of animals with each chromosome haplotype is listed at the bottom of each column. (C) Haplotype

analysis of *Frg1* in the B6C3-CAST cross. Black squares indicate transmission of the B6C3 allele, white squares of the CAST allele. All *D8Mit* dinucleotide markers were typed in this cross previously. Haplotypes marked with an asterisk are from affected animals. No recombinants have been observed between *D8Mit9* and *myd* in 275 chromosomes (Mills et al. 1996c).



**Fig. 3.** Northern blot containing 20 µg of total RNA from tissues isolated from one normal and two *myd* mice. The filter was hybridized with either a probe for the mouse *Frg1* cDNA clone MC10 or an 18S rRNA probe. With *Frg1*, a 1.2-kb transcript was detected in all tissues, with highest levels in testes. There are no significant differences in the levels of *Frg1* mRNA between normal and *myd* mice.

transcripts of 1.2, 1.9, and 5 kb, although the 1.9 kb transcript was detected only in fetal tissue. The probe used in our study did not contain the entire cDNA, which may account for this discrepancy. However, there is no evidence that the human FRG1 gene undergoes alternative splicing (van Deutekom et al. 1996). Further studies on the expression profile of *Frg1* will be needed to investigate these differences. The mouse EST used to design *Frg1* primers was isolated from a fetal ovary cDNA library in an approach designed to identify genes involved in gametogenesis (López-Alanón and del Mazo 1995). Consistent with this, by Northern blot analysis much higher expression levels of *Frg1* were seen in testis, and it seems likely that a function of this gene may be related to gametogenesis.

There are at least 14 genes from human Chr 4q28–q35 with identified homologs in a span of approximately 20 cM on mouse Chr 8 (Mathews and Mills 1996). We have extended this region with homology of synteny on mouse Chr 8 to include *Frg1*. It is

not known whether there is linkage conservation between mouse and human because many of these genes have been mapped in different crosses. However, the current synteny homology maps of human Chr 4q35 and mouse Chr 8 suggest a general relationship between the most distal genes on human 4q and the most proximal genes in the mouse (Mathews and Mills 1996). Our data show linkage conservation between *Frg1*, *Ant1*, and *Clc3*, which all map proximal to the *myd* locus.

Phenotypically the *myd* mouse is a good candidate as a homolog of FSHD (Mathews et al. 1995a). However, if the relative gene order is conserved between human and mouse, the human homolog of *myd* should map to a more proximal region of Chr 4q than FRG1, and the two mutations may not be homologous. At present, however, the mouse map is still at a relatively low resolution, and small inversions and rearrangements could have resulted in different locations of the FSHD/*myd* gene. Ultimately, the relationship between FSHD and *myd* can be determined only by cloning of the genes responsible for each disorder.

**Acknowledgments.** The authors thank Dr. Pete Scambler for the mouse cDNA library and the MRC HGMP Resource Centre UK for the interspecific backcross DNAs. This study was funded by grants from the Muscular Dystrophy Group of Great Britain, The Muscular Dystrophy Association (USA), Princes Beatrix Funds, Association Française contre les myopathies, and National Institutes of Health grant K08NS01591.

**References**

Altherr MR, Bengtsson U, Markovich RP, Winokur ST (1995) Efforts toward understanding the molecular basis of facioscapulohumeral dystrophy. *Muscle Nerve Suppl* 2, S32–S38  
 Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215, 403–410  
 Breen M, Deakin LBM, Miller S, Sibson R, Tartelin E, Avner P, Bourgade F, Guenet J-L, Montagutelli X, Poirier C, Simon D, Tailor D, Bishop M,

- Kelly M, Rysavy F, Rastan S, Norris D, Shepherd D, Abbott C, Pilz A, Hodge S, Jackson I, Boyd Y, Blair H, Maslen G, Todd JA, Reed PW, Stoye J, Ashworth A, McCarthy L, Cox R, Schalkwyk L, Lehrach H, Klose J, Gangadharan U, Brown SDM (1994) Towards high resolution maps of the mouse and human genomes—a facility for ordering markers to 0.1cM resolution. *Hum Mol Genet* 3, 621–627
- Chisholm D (1989) A convenient moderate-scale procedure for obtaining DNA from bacteriophage lambda. *Biotechniques* 7, 21–23
- Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z, Dredge R, Daly MJ, Ingalls KA, O'Connor TJ, Evans CA, DeAngelis MM, Levinson DM, Kruglyak L, Goodman N, Copeland NG, Jenkins NA, Hawkins TL, Stein L, Page DC, Landers ES (1996) A comprehensive genetic map of the mouse genome. *Nature* 380, 149–152
- Genetics Computer Group (1994) *Program Manual for the Wisconsin Package* (Madison, WI: Genetics Computer Group)
- Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C, van Deutekom JCT, Francis F, Sharpe PT, Hofker M, Frants RR, Williamson R (1994) Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. *Hum Mol Genet* 3, 1287–1295
- Lane PW, Beamer TC, Myers DD (1976) Myodystrophy, a new myopathy on chromosome 8 of the mouse. *J Hered* 67, 135–138
- Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Wallace DC (1989) A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. *J Biol Chem* 264, 13998–14004
- López-Alanón DM, del Mazo J (1995) Cloning and characterization of genes expressed during gametogenesis of female and male mice. *J Reprod Fertil* 103, 323–329
- Lunt PW, Harper PS (1991) Genetic counselling in facioscapulohumeral muscular dystrophy. *J Med Genet* 28, 665–664
- Lyle R, Wright TJ, Clark LN, Hewitt JE (1995) The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. *Genomics* 28, 389–397
- Manly KF (1993) A Macintosh program for storage and analysis of experimental genetic mapping data. *Mamm Genome* 4, 303–313
- Mathews KD, Mills KA (1996) The molecular genetics of human facioscapulohumeral muscular dystrophy and the *myodystrophy* mouse. *Curr Opin Neurol* 9, 394–399
- Mathews KD, Mills KA, Bailey H, Schelper R, Murray J (1995a) Mouse myodystrophy (*myd*) mutation: refined mapping in an interval flanked by homology with distal human 4q. *Muscle Nerve Suppl* 2, S98–S102
- Mathews KD, Rapisarda D, Bailey HL, Murray JC, Schelper RL, Smith R (1995b) Phenotypic and pathological evaluation of the *myd* mouse, a candidate model for facioscapulohumeral dystrophy. *J Neuropathol Exp Neurol* 54, 601–606
- Mills KA, Mathews KD, Scherpbier-Heddema T, Schelper RL, Schmalzel R, Bailey HL, Nadeau JH, Beutow KH, Murray JC (1995) Genetic mapping near the *myd* locus on mouse chromosome 8. *Mamm Genome* 6, 278–280
- Mills KA, Ellison JW, Mathews KD (1996a) The *Ant1* gene maps near *Klk3* on proximal mouse chromosome 8. *Mamm Genome* 7, 707
- Mills KA, Mathews KD, Scherpbier-Heddema T, Beutow KH, Baldini A, Ballabio A, Borsani G (1996b) Genetic and physical mapping of a voltage-dependent chloride channel gene to human 4q32 and to mouse 8. *Genomics* 36, 374–376
- Mills KA, Tresnak J, Mathews KD (1996c) Physical mapping and sequence analysis of the *myd* critical region. *Am J Hum Genet* 59, A308
- Rouer E (1994) Direct neutralization of alkaline-denatured plasmid DNA in sequencing protocol by the sequencing reagent itself. *Nucleic Acids Res* 22, 4844
- van Deutekom JCT, Wijmenga C, van Tienhoven EAE, Gruter A-M, Hewitt JE, Padberg GW, van Ommen G-JB, Hofker MH, Frants RR (1993) FSHD associated rearrangements are due to deletion of integral copies of a 3.2kb tandemly repeated unit. *Hum Mol Genet* 2, 2037–2042
- van Deutekom JCT, Hofker MH, Romberg S, van Geel M, Rommens J, Wright TJ, Hewitt JE, Padberg GW, Wijmenga C, Frants RR (1995) Search for the FSHD gene using cDNA selection in a region spanning 100kb on chromosome 4q35. *Muscle Nerve Suppl.* 2, S19–S26
- van Deutekom JCT, Lemmers RJLF, Grewal PK, van Geel M, Romberg S, Dauwerse HG, Wright TJ, Padberg GW, Hofker MH, Hewitt JE, Frants RR (1996) Identification of the first gene (*FRG1*) from the FSHD region on human chromosome 4q35. *Hum Mol Genet* 5, 581–589
- Williamson P, Holt S, Boyd Y (1995) A somatic cell hybrid panel for mouse gene mapping characterized by PCR and FISH. *Mamm Genome* 6, 429–432
- Winokur ST, Bengtsson U, Feddersen J, Mathews KD, Weiffenbach B, Bailey H, Markovich RP, Murray JC, Wasmuth JJ, Altherr MR, Schutte BC (1994) The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease. *Chromosome Res* 2, 225–234